Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: A case-control study

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 4, 2004, Pages 798-802

  Senneville, Eric ^a   Legout, Laurence ^a   Valette, Michel ^a   Yazdanpanah, Yazdan ^a   Giraud, François ^b   Beltrand, Eric ^a   Obert, Guillaume ^a   Dubreuil, Luc ^a   Migaud, Henri ^b   Mouton, Yves ^a  

^a Dron Hospital   (France)

^b Faculty of Lille   (France)

Author keywords

Myelosuppression; Oxazolidinones; Toxicity

Indexed keywords

CEFEPIME; CLINDAMYCIN; HEMOGLOBIN; LEVOFLOXACIN; LINEZOLID; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ADULT; AGED; ALCOHOLISM; ANEMIA; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD TRANSFUSION; CASE CONTROL STUDY; CHRONIC OSTEOMYELITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG WITHDRAWAL; FEMALE; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN DETERMINATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MEDICAL RECORD; PERIPHERAL NEUROPATHY; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

ACETAMIDES; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OSTEOMYELITIS; OXAZOLIDINONES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 6344231849     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh409     Document Type: Article

References (26)

1. Lew, D. P. & Waldvogel, F. A. (1997). Osteomyelitis. New England Journal of Medicine 336, 999-1007.
2. Critchley, I. A., Draghi, D. C., Sahm, D. F. et al. (2003). Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. Journal of Antimicrobial Chemotherapy 51, 639-49.
3. Norden, C. W. & Shaffer, M. (1983). Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with vancomycin and rifampin. Journal of Infectious Diseases 147, 352-7.
4. Norden, C. W. (1988). Lessons learned from animal models of osteomyelitis. Reviews of Infectious Diseases 10, 103-10.
5. Drancourt, M., Stein, A., Argenson, J. N. et al. (1993). Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopaedic implants. Antimicrobial Agents and Chemotherapy 37, 1214-8.
6. Senneville, E., Yazdanpanah, Y., Cazaubiel, M. et al. (2001). Rifampin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. Journal of Antimicrobial Chemotherapy 39, 235-40.
7. Zimmerli, W., Widmer, A. F., Blatter, M. et al. (1998). Role of rifampin for treatment of orthopaedic implant-related staphylococcal infections. Journal of the American Medical Association 279, 1537-41.
8. Drancourt, M., Stein, A., Argenson, J. N. et al. (1997). Oral treatment of Staphylococcus spp. Infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. Journal of Antimicrobial Chemotherapy 39, 235-40.
9. Melzer, M., Goldsmith, D. & Gransden, W. (2000). Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving haemodialysis and with persistent methicillin-resistant Staphylococcus aureus and Enterococcus bacteremias. Clinical Infectious Diseases 31, 208-9.
10. Basseti, M., Di Baggio, A., Cenderello, G. et al. (2001). Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA). Journal of Infection 43, 148-9.
11. Till, M., Wixson, R. L. & Pertel, P. E. (2002). Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium. Clinical Infectious Diseases 34, 1412-4.
12. Lipsky, B. (2004). Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clinical Infectious Diseases 38, 17-24.
13. Monson, T., Schichman, S. A. & Zent, C. S. (2002). Linezolid-induced pure red cell aplasia. Clinical Infectious Diseases 35, e29-e31.
14. Green, S. L., Maddox, J. C. & Huttenbach, E. D. (2001). Linezolid and reversible myelosuppression. Journal of the American Medical Association 285, 1291.
15. Gerson, S., Kaplan, S., Bruss, J. et al. (2002). Hematologic effects of linezolid: summary of clinical experience. Antimicrobial Agents and Chemotherapy 46, 2723-6.
16. Kutter, D. J. & Tillotson, G. S. (2001). Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy 21, 1010-3.
17. Zyvox [package insert]. (2000). Kalamazoo, MI: Pharmacia Upjohn.
18. Chien, J. W., Kucia, M. L. & Salata, R. A. (2000). Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clinical Infectious Diseases 30, 146-51.
19. Li, Z., Willke, R. J., Pinto, L. A. et al. (2001). Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 21, 263-74.
20. Gander, S., Hayward, K. & Finch, R. (2002). An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model. Journal of Antimicrobial Chemotherapy 49, 301-8.
21. Gunderson, B., Ibrahim, K., Peloquin, C. et al. (2003). Comparison of linezolid activities under aerobic and anaerobic conditions against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Antimicrobial Agents and Chemotherapy 47, 398-9.
22. Jacqueline, C., Caillon, J., Le Mabecque, V. et al. (2003). In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. Journal of Antimicrobial Chemotherapy 51, 857-64.
23. French, G. (2003). Safety and tolerability of linezolid. Journal of Antimicrobial Chemotherapy 51, ii45-ii53.
24. Birmingham, M. C., Rayner, C. G., Meagher, A. K. et al. (2003). Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clinical Infectious Diseases 36, 159-68.
25. Lund, J. E. & Brown, P. K. (1997). Hypersegmented megakaryocytes and megakaryocytes with multiple separate nuclei in dogs treated with PNU-100592, an oxazolidinone antibiotic. Toxicology and Pathology 25, 339-43.
26. Gonzales, R. D. & Schreckenberger, P. C. (2001). Infections due to vancomycin Enterococcus faecium resistant to linezolid [Letter]. Lancet 357, 1179.